The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 18, 2014

Filed:

May. 07, 2012
Applicants:

Michael Prime, Abingdon, GB;

Stephen Martin Courtney, Stanford in the Vale, GB;

Richard Marston, Wantage, GB;

Celia Dominguez, Los Angeles, CA (US);

Douglas Macdonald, Los Angeles, CA (US);

John Wityak, Carlsbad, CA (US);

Inventors:

Michael Prime, Abingdon, GB;

Stephen Martin Courtney, Stanford in the Vale, GB;

Richard Marston, Wantage, GB;

Celia Dominguez, Los Angeles, CA (US);

Douglas MacDonald, Los Angeles, CA (US);

John Wityak, Carlsbad, CA (US);

Assignee:

CHDI Foundation, Inc., New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/445 (2006.01); C07D 211/96 (2006.01); C07D 409/12 (2006.01); C07D 205/04 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 207/48 (2006.01); C07D 401/14 (2006.01); C07D 401/12 (2006.01);
U.S. Cl.
CPC ...
C07D 205/04 (2013.01); C07D 211/96 (2013.01); C07D 409/12 (2013.01); C04D 413/12 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 207/48 (2013.01); C07D 401/14 (2013.01); C07D 401/12 (2013.01);
Abstract

Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.


Find Patent Forward Citations

Loading…